FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Leerink Partnrs raised their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of ($1.50) per share for the year, up from their prior estimate of ($2.25). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.03) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' FY2026 earnings at ($3.25) EPS and FY2028 earnings at ($2.95) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

STOK has been the topic of a number of other reports. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a "buy" rating and a $24.00 price target on the stock. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They set an "outperform" rating and a $18.00 target price for the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, January 8th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of "Buy" and an average price target of $21.29.

Stoke Therapeutics Stock Up 9.5 %

STOK stock traded up $1.09 during midday trading on Friday, hitting $12.61. The company's stock had a trading volume of 832,541 shares, compared to its average volume of 851,224. The firm has a market capitalization of $668.16 million, a price-to-earnings ratio of -6.01 and a beta of 0.95. Stoke Therapeutics has a 12 month low of $4.09 and a 12 month high of $17.58. The company has a 50 day moving average of $11.07 and a two-hundred day moving average of $12.65.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Stoke Therapeutics during the fourth quarter valued at about $124,000. Intech Investment Management LLC acquired a new position in shares of Stoke Therapeutics in the third quarter valued at about $160,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after purchasing an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. purchased a new stake in Stoke Therapeutics in the third quarter valued at approximately $192,000. Finally, Rhumbline Advisers increased its holdings in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after buying an additional 2,787 shares during the period.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,170 shares of the company's stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the sale, the chief executive officer now owns 68,671 shares in the company, valued at $877,615.38. This represents a 8.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Barry Ticho sold 13,945 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $178,217.10. Following the sale, the insider now directly owns 47,332 shares in the company, valued at $604,902.96. This trade represents a 22.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,849 shares of company stock worth $809,421 in the last ninety days. 11.30% of the stock is owned by company insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.